Daraxonrasib: A Daily Pill That Doubles Survival in the World's Deadliest Cancer
Daraxonrasib is the most consequential pancreatic-cancer result of the modern oncology era and reframes RAS — long considered "undruggable" — as the new central battleground of solid-tumour therapy.
TL;DR
- First meaningful survival win in PDAC in 40+ years — median OS 13.2 months vs 6.7 on chemotherapy.
- 60% reduction in risk of death (HR 0.40); progression-free survival also roughly doubled.
- Oral, once-daily pill — no infusion chair, no port, manageable side-effect profile (rash, nausea, mild LFT changes).
- Mechanism is the story: a pan-RAS(ON) inhibitor that blocks the active form of all major RAS mutations — applicable to ~25% of all human cancers.
- Regulatory path: Revolution Medicines expected to file for FDA accelerated approval H2 2026; likely 2027 launch.
- Watch-outs: cost (analyst estimates US$200k+/year), resistance mechanisms already emerging, and access in LMICs.
The breakthrough
A once-daily oral pill called daraxonrasib has become the first therapy in more than four decades to meaningfully extend life in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) — a disease so lethal that fewer than 13% of patients survive five years from diagnosis. In results unveiled at the American Society of Clinical Oncology (ASCO) Annual Meeting on 31 May and published simultaneously in the New England Journal of Medicine, the drug doubled median overall survival and cut the risk of death by 60% compared with standard second-line chemotherapy.
Cancer specialists, normally careful with their language, have not been restrained. Dr Rachna Shroff, chief of oncology at the University of Arizona Cancer Center, said she "actually started crying" when she first saw the data. Pharmaphorum dubbed the result a "grand slam." The Washington Post called it a "landmark." The Guardian labelled it a "gamechanger."
What the trial showed
The Phase 3 RASolute 302 trial, sponsored by Revolution Medicines, randomised 500 patients with metastatic PDAC whose disease had progressed after first-line chemotherapy. Patients received either daraxonrasib monotherapy or investigator's choice of second-line chemotherapy. Headline results:
| Endpoint | Daraxonrasib | Chemotherapy |
|---|---|---|
| Median overall survival | 13.2 months | 6.7 months |
| Reduction in risk of death | 60% | — |
| Grade ≥3 (severe) adverse events | 43.6% | 57.5% |
| Discontinuation due to side-effects | 1.2% | 11.2% |
Critically, daraxonrasib worked across all comers — patients were not preselected for a specific mutation. Around 90% of pancreatic cancers carry a mutation in the KRAS oncogene, a target that had eluded drug developers for over 40 years because of its smooth, "undruggable" surface.
How it works
Daraxonrasib is a pan-RAS(ON) inhibitor. Earlier KRAS drugs (such as sotorasib and adagrasib) only hit a single mutation, KRAS G12C, which represents a small slice of pancreatic cases. Revolution Medicines' molecule instead targets the active "ON" state of multiple RAS variants — including G12D, G12V, G12R and wild-type RAS — by binding a chaperone protein, cyclophilin A, to form a "molecular glue" complex that blocks downstream growth signalling.
In practical terms, that means one pill can address the dominant oncogenic driver in the vast majority of PDAC tumours, not a niche minority.
Why this matters
- Scale of unmet need. Pancreatic cancer kills roughly 466,000 people globally each year and is on track to become the second-leading cause of cancer death in many developed economies by 2030. Until now, second-line options offered weeks — not months — of additional life.
- Tolerability. Severe side-effect rates were lower than chemotherapy, and only 1.2% of patients had to stop treatment. For a population already exhausted by first-line therapy, this is clinically and humanely significant.
- Beyond pancreas. Revolution has parallel trials underway in non-small-cell lung cancer, colorectal cancer and other RAS-driven tumours. A successful read-out would reshape oncology across multiple high-incidence diseases.
- Earlier-line potential. Investigators are now planning studies in first-line and neoadjuvant settings, exploring whether tumour shrinkage could make more patients eligible for curative surgery — historically only possible in ~15–20% of cases at diagnosis.
The cautionary notes
- It is not a cure. Dr Zev Wainberg (UCLA), who co-led the study, was explicit: "While not curing the cancer, it is a very large step forward." Median survival has roughly doubled, but most patients will still relapse.
- Resistance will emerge. As with every targeted therapy, tumour heterogeneity and bypass signalling are expected. Combination regimens — daraxonrasib plus chemotherapy, immunotherapy or other RAS-pathway agents — are already being designed.
- Access and cost. Pricing has not been announced. Pan-RAS therapies are expected to launch in the US$200,000+ per year range typical of modern targeted oncology drugs, raising near-term equity questions for public payers, including in Australia where PBS listing timelines for novel oncology agents have lengthened.
- Regulatory path. Revolution Medicines is expected to file with the FDA in the second half of 2026, with EMA and TGA submissions to follow. A priority-review designation is widely anticipated.
Industry context
The pan-RAS category is now the hottest space in oncology drug development, with more than a dozen candidates in clinical testing from companies including Mirati/Bristol-Myers Squibb, Boehringer Ingelheim, Astellas and several Chinese biotechs. Revolution Medicines' lead — built on a near-decade head start in RAS chaperone biology — looks durable, and the company's share price has surged roughly 40% since the data dropped.
For health systems, the strategic message is that KRAS, the most-mutated oncogene in human cancer, is no longer untouchable. That single shift will reverberate through pipelines, payer models and oncology workforce planning for the rest of this decade.
Sources
- Wainberg et al., NEJM, 31 May 2026
- ASCO 2026 Annual Meeting plenary, 31 May 2026
- The Guardian — "Daily pill can double survival time for world's deadliest cancer, trial shows" (31 May 2026)
- Washington Post — "'Landmark' pancreatic cancer drug keeps patients alive for twice as long" (31 May 2026)
- CNN, CNBC, NPR coverage (31 May – 2 June 2026)
- Pharmaphorum — "ASCO26: Revolution's 'grand slam' data in pancreatic cancer" (31 May 2026)
- New York Post — "'Grand slam' pill doubles survival rate for third deadliest cancer" (2 June 2026)
